Cytoreg / Cytorex - LARVOL DELTA

Efficacy of Cytoreg in the treatment of diabetic foot disease. (PubMed, J Wound Care) - "Significant increases in arterial haemoglobin and arterial oxygen partial pressure (p<0.05) were observed, and significant decreases were measured in the levels of glycosylated haemoglobin, aspartate aminotransferase, glutamic-pyruvic transaminase, creatine and urea (p<0.05). The results of this study justify an expanded clinical study for the treatment of DFUs with Cytoreg."

Journal • Diabetes • Infectious Disease • Metabolic Disorders

Effect of an ionic antineoplastic agent Cytoreg on blood chemistry in a Wistar rat model. (PubMed, Med Gas Res) - "The study was approved by the Bioethics Committee of the University of the Andes, Venezuela (CEBIOULA) (approval No. 125) on November 3, 2019."

Journal • Preclinical • Oncology

Evaluation of dermal corrosion and irritation by Cytoreg in rabbits. (PubMed, Toxicol Rep) - "Dose site three was wrapped for 4 h. One hour after unwrapping the third site, all three test sites were observed for skin irritation and/or corrosion, and again at 24, 48 and 72 h after final unwrap. Based on the 4 -h dose scores through 72 h, the primary irritation index (PII) for Cytoreg is 0.00 at 2 % and 4 %, with a descriptive rating of non-irritating, and 0.25 PII with slightly irritating rating at 100 %."

Journal • Preclinical • Immune Modulation • Inflammation